Inflammatory Bowel Disease (IBD)

An umbrella term for chronic relapsing-remitting inflammatory conditions of the gastrointestinal tract, principally crohns disease (CD; transmural, any GI segment) and ulcerative colitis (UC; mucosal, colon only). Approximately 6 million patients worldwide. IBD represents the most direct manifestation of gut dysbiosis, barrier failure, and immune dysregulation — the same triad that metals produce — making it a central disease in the metallomics-microbiome framework.

Metallomic Signature

Iron Dysregulation: The Defining Metal Feature

  • Iron deficiency anemia affects 36-76% of IBD patients, driven by chronic blood loss, malabsorption, and inflammation-mediated iron sequestration.
  • hepcidin is elevated by IL-6 during IBD flares, blocking ferroportin-mediated iron export from enterocytes and macrophages — trapping iron intracellularly while producing systemic deficiency.
  • This creates a paradox: intracellular iron excess (promoting oxidative stress and potentially ferroptosis) alongside systemic iron deficiency (causing anemia and fatigue).
  • Oral iron supplementation worsens dysbiosis by providing growth substrate for siderophilic pathogens (Enterobacteriaceae, E. coli) while suppressing beneficial anaerobes.

Zinc Depletion

  • Zinc is depleted in IBD via diarrheal losses, malabsorption, and increased urinary excretion during inflammation.
  • Zn deficiency impairs intestinal barrier integrity (ZO-1, claudin-1 expression), wound healing, and immune function.
  • The ZIP8 (SLC39A8) A391T variant in Crohn's disease directly links zinc transport dysfunction to barrier integrity, microbiome composition, and inflammation [1].

Selenium and Other Trace Elements

  • Selenium significantly lower in both CD and UC vs controls; impairs selenoprotein-dependent antioxidant defense (GPx, TrxR) [2].
  • Manganese depleted in UC patients. Nickel elevated in active CD vs inactive UC [2].
  • Thallium positively associated with UC disease activity — a novel finding [2].

Dysbiosis Signature

IBD dysbiosis is among the most characterized in the literature:

  • Depleted: faecalibacterium prausnitzii (most consistent finding), Roseburia, blautia, bifidobacterium, Prevotella — all major short chain fatty acids producers.
  • Enriched: Enterobacteriaceae (adherent-invasive E. coli in CD), Fusobacterium, Ruminococcus gnavus.
  • Firmicutes/Bacteroidetes ratio altered; reduced microbial diversity overall.
  • This signature overlaps substantially with metal-induced dysbiosis patterns, raising the question of whether environmental metal exposure contributes to IBD incidence.

Biomarkers

  • Fecal calprotectin: The gold-standard non-invasive biomarker for intestinal inflammation in IBD. S100A8/A9 protein released by activated neutrophils; sequesters zinc and manganese as part of nutritional immunity. Correlates with endoscopic disease activity.
  • CRP, SAA: Systemic inflammation markers; CRP elevated in active disease.
  • Fecal lactoferrin: Iron-binding neutrophil protein; elevated in active IBD.
  • IL-6, TNF-alpha, IL-1beta: Pro-inflammatory cytokines driving disease pathology.

IBD-CVD Comorbidity

IBD patients have significantly increased cardiovascular disease risk:

  • 2x increased heart failure risk; 19% increase in HF risk up to 20 years post-diagnosis.
  • Shared mechanisms: chronic inflammation, endothelial dysfunction, tmao elevation, dysbiosis-driven LPS translocation [3].
  • calprotectin and CRP predict both IBD activity and CVD risk.

<!— Intervention/treatment content moved to Cureva per public/clinical boundary policy —>

Key Sources

Connections

  • crohns disease — transmural IBD subtype; ZIP8 variant links metal transport to pathogenesis
  • calprotectin — gold-standard IBD biomarker; metal-sequestering antimicrobial protein
  • hepcidin — iron-regulatory hormone elevated in IBD, driving the anemia-of-inflammation paradox
  • ferroptosis — intracellular iron trapping during hepcidin elevation may promote ferroptotic cell death
  • short chain fatty acids — SCFA producer depletion is the functional consequence of IBD dysbiosis
  • dysbiosis — IBD has the most characterized dysbiosis signature in the literature
  • inflammation — chronic NF-kB-driven inflammation is the hallmark of IBD
  • cardiovascular disease — IBD patients at significantly increased CVD risk via shared inflammatory mechanisms
  • nutritional immunity — calprotectin and lactoferrin are nutritional immunity effectors elevated in IBD
  • metal disease matrix — IBD is a key disease in the metal-disease interaction landscape
  • prebiotics — prebiotic fiber supports SCFA producer recovery in IBD remission maintenance
  • fecal microbiota transplant — strongest evidence in UC subtype; 25-35% remission; donor diversity predicts response
  • microbial biomarkers — fecal calprotectin and microbial diversity as non-invasive IBD monitoring tools
  • microbiome derived metabolites — SCFA depletion, bile acid alterations, and tryptophan shunting in IBD
  • biomarkers — calprotectin, CRP, hepcidin, and metallomic panels for disease activity tracking

References (11)

  1. ★Yang JC, Zhao M, Chernikova D et al. (2024). ZIP8 A391T Crohn's Disease-Linked Risk Variant Induces Colonic Metal Ion Dyshomeostasis, Microbiome Compositional Shifts, and Inflammation. Digestive Diseases and Sciences. doi:10.3389/fimmu.2023.1183914
  2. Amerikanou C, Karavoltsos S, Gioxari A et al. (2022). Clinical and inflammatory biomarkers of inflammatory bowel diseases are linked to plasma trace elements and toxic metals; new insights into an old concept. Frontiers in Nutrition. doi:10.3389/fnut.2022.997356
  3. Camila Sanchez Cruz, Anahi Rojas Huerta, Jesus Lima Barrientos et al. (2024). Inflammatory Bowel Disease and Cardiovascular Disease: An Integrative Review With a Focus on the Gut Microbiome. Cureus. doi:10.7759/cureus.65136
  4. Zhu R, He P, Liu Z et al. (2021). Editorial: Microbiome in IBD: From Composition to Therapy. Frontiers in Pharmacology. doi:10.3389/fphar.2021.721992
  5. Rashed R, Valcheva R, Dieleman LA (2022). Manipulation of Gut Microbiota as a Key Target for Crohn's Disease. Frontiers in Medicine. doi:10.3389/fmed.2022.887044
  6. Borghini R, Porpora MG, Casale R et al. (2020). Irritable Bowel Syndrome-Like Disorders in Endometriosis: Prevalence of Nickel Sensitivity and Effects of a Low-Nickel Diet. An Open-Label Pilot Study. Nutrients. doi:10.3390/nu12082277
  7. Syer SD, Blackler RW, Martin R et al. (2015). NSAID Enteropathy and Bacteria: A Complicated Relationship. Journal of Gastroenterology. doi:10.1007/s00535-014-1032-1
  8. Fabian Mermans, Evelien Heiremans, Maud Van Belleghem et al. (2019). Nonsteroidal Anti-Inflammatory Drugs as Therapeutic Allies of the Gut Microbiome on Chronic Inflammation. Facta Universitatis Series Medicine and Biology. doi:10.22190/FUMB201222013M
  9. Li P, Zhang T, Xiao Y et al. (2019). Timing for the Second Fecal Microbiota Transplantation to Maintain the Long-Term Benefit from the First Treatment for Crohn's Disease. Applied Microbiology and Biotechnology. doi:10.1007/s00253-018-9447-x
  10. Sokol H, Landman C, Seksik P et al. (2020). Fecal Microbiota Transplantation to Maintain Remission in Crohn's Disease: A Pilot Randomized Controlled Study. Microbiome. doi:10.1186/s40168-020-0792-5
  11. Shen J, Zuo ZX, Mao AP (2014). Effect of Probiotics on Inducing Remission and Maintaining Therapy in Ulcerative Colitis, Crohn's Disease, and Pouchitis: Meta-analysis of Randomized Controlled Trials. Inflammatory Bowel Diseases. doi:10.1097/01.MIB.0000437495.30052.be

Related Articles